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622 LETTERS TO THE EDITORThe patient was enrolled in a gene therapy trial based on
autologous gene-corrected hematopoietic stem cells
(clinicaltrials.gov #NCT01515462), mobilized with G-CSF and
plerixafor. Treatment with anakinra was discontinued 48 hours
before mobilization, but was soon restarted because of the in-
crease in white blood cells and inflammation indexes with exacer-
bation of skin lesions, arthralgia, and hematuria, and led again to a
rapid laboratory and clinical remission (data not shown). Notably,
the use of anakinra allowed a successful mobilization with G-CSF
without the occurrence of other autoinflammatorymanifestations.
To our knowledge, this is the first reported case of use of IL-1R
blocker in a patient with WAS, with clinical benefit.
This case is very emblematic for several reasons. Whole-
genome sequencing complemented by specific breakpoint
sequencing allowed the identification of the inversion with
intact exon sequences, elucidating the previous normal genetic
analysis. Complex genomic rearrangements involving inversions
are generally noncanonical gene conversion events6 and could
have occurred in an ancestor allele in the family through a de
novo mutation occurring in the mother.
Autoimmune and autoinflammatory manifestations in patients
with WAS typically present early in life, are often refractory to
therapy, and are associated with a worse clinical prognosis and an
increased risk of developing a malignancy.3,7 Our patient’s autoin-
flammatory manifestations were resistant to several immunosup-
pressive drugs and the use of CyA was associated with a severe
viral complication. Anakinra dramatically improved PG, vasculitis,
and arthritis, showed a good safety profile, and allowed stabiliza-
tion of the patient for definitive treatment. The response to anakinra
suggests that the dysregulation of the innate immune system is
involved in the genesis of autoinflammatory manifestations in pa-
tients with WAS and shows that IL-1 may serve in selected cases
as a target for therapy, avoiding the use of other classes of immuno-
suppressors that can increase the risk for severe infections.
It has been hypothesized that defects in chemotaxis and
podosomes formation in WASp-deficient cells may favor the
onset of autoinflammatory manifestations. In addition, a recent
study in a patient with aggressive PG showed a critical role for
proline-serine-threonine phosphatase interacting protein 1, which
is involved in cytoskeletal regulatory functions through interac-
tion with WASp, in the Pyogenic Arthritis, Pyoderma gangreno-
sum, and Acne syndrome.8 A greater understanding of the role of
WASp in inflammation and of potential pathways that may be tar-
geted therapeutically to modulate immunity in WAS is desirable
to improve the management of the affected patients while waiting
for definitive treatment by stem cell transplantation or gene
therapy.
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http://dx.doi.org/10.1016/j.jaci.2016.03.007Functional changes in gut micro-
biota during hematopoietic stem
cell transplantation for severe
combined immunodeficiencyTo the Editor:
Severe combined immunodeficiencies (SCIDs), a group of rare,
inherited conditions characterized by T lymphocytopenia, are
fatal before age 1 year without hematopoietic stem cell trans-
plantation (HSCT). Graft-versus-host disease (GvHD) and
bacteremia cause post-HSCT morbidity and mortality. Early
studies showed that germ-free mice fail to develop GvHD, thus
demonstrating a role for microbiota in GvHD pathogenesis.1 In
FIG 1. PLS-DA showing separation of metabolite profiles by pre- or post-HSCT status. X/Y overview values
for pre- and post-HSCT: R25 0.77, Q25 0.6; values >0.5 demonstrate data passes validation and are robust
and reproducibly predictive of pre- and post-HSCT grouping.
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dominance are associated with development of gut GvHD2 and
bacteremia3 and low microbial diversity is predictive of
transplant-related mortality.4 We previously demonstrated that
bacterial taxonomy of the gut microbiota in 3 patients with
SCID changed over time, producing distinct pre- and
post-HSCT microbiota populations with low microbial diversity
and bacterial dominance.5 Recently, research has focused on
microbiota function in addition to taxonomy because microbial
products can have immunoregulatory roles.
We studied changes in gut microbiota functional profiles
through HSCT for 3 patients with SCID who underwent a
transplant who have had their microbiota structure previously
published.5 Clinical data and daily stool samples were collected
following informed parental consent. Stool samples were stored
at 2808C before analysis. Disease, demographic characteristics,
and HSCT details for the 3 patients are reproduced from
previously published data (see Table E1 in this article’s Online
Repository at www.jacionline.org5). Details of computational
prediction of microbiota functions and metabolic profiling are
provided (see this article’s Methods section in the Online
Repository at www.jacionline.org).
Metabolomic profiles obtained from ultra-performance liquid
chromatography tandem mass spectrometry (UPLC-MS/MS) of
54 stool samples spanning pre- and post-HSCT were analyzed
using partial least squares discriminant analysis (PLS-DA; Fig 1).
Combining all patients in one analysis shows that samples can be
separated into pre- and post-HSCT groups. The pre-HSCT
samples most closely related to the post-HSCT group were
collected in the few days preceding HSCT. Masses and retentiontimes of 5454 metabolites found across the 54 samples are pro-
vided (see UPLC-MS Data file in this article’s Online Repository
at www.jacionline.org). Coefficient analysis demonstrates that
280 metabolites were significantly associated with pre-HSCT
status and 1060with post-HSCT status. Because of the large num-
ber of associated metabolites and limitations in metabolomics
analysis, further metabolite identification was not performed.
The results of the PLS-DA analysis of the gut metabolome
based on UPLC-MS/MS are similar to results for microbiota
structure5: samples can be separated into pre- and post-HSCT
groups and reveal a gradual shift from a pre- to post-HSCT
metabolome, suggesting that HSCT does not cause sudden
profound shifts in microbial function. The implications of these
shifts for patients with SCID are not yet clear. The changes
seem to be influenced by new therapeutic strategies such as
probiotics. However, unlike microbiome analysis, identification
of metabolites based on neutral mass is troublesome because of
underdeveloped databases of stool metabolites. Over time these
limitations will resolve, improving annotation of significant
metabolites. Nonetheless, profiling these functional small
molecules offers important insights into host and microbe activity
through transplant.
The PLS-DA model developed was robust and reproducibly
predictive of pre- and post-HSCT grouping, as demonstrated by
X/Yoverview values of more than 0.5. Further cross-validation is
outside the scope of our study but would require a separate cohort
to fully test the model.
Predicted microbiota functions were computationally derived
from 88 16S ribosomal RNA (rRNA) sequences spanning
pre- and post-HSCT (MG-RAST accession numbers
FIG 2. Level 2 PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved states)
analysis for patients A (A), B (B), and D (C). T (blue)—day of HSCT. N (green)—neutrophil engraftment.
Conditioning (yellow): Treo/flu/C1H—treosulfan, fludarabine, Campath. Antibiotics (black): T—teicoplanin;
M—meropenem; S—co-trimoxazole; C—ceftazidime; V—vancomycin; A—amikacin; Aug—co-amoxiclav.
Clinically significant complications noted (orange).
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tion of communities by reconstruction of unobserved states), a
validated bioinformatics tool.6 All patients showed fluctuations
in relative abundance of predicted microbiota functions (Fig 2).
Changes in bacterial functions involved in bacterial motility
and membrane transport accounted for most of the fluctuation
observed (see Fig E1 this article’s Online Repository at
www.jacionline.org). Only descriptive analysis was undertaken
to avoid inferring more generalizable conclusions from a
predictive computational modeling technique. As such we did
not undertake PLS-DA modeling to demonstrate pre- and
post-HSCT groups and further transcriptomic work is required.
Patient A who presented at age 7 months with pneumocystis
pneumonitis showed more fluctuation in bacterial motility and
membrane transport predicted functions (Fig E1, A) than did
patients B and D who were under 1 week old at presentation
(Fig E1, B and C, E and F). Increases in cell motility functions
were associated with the appearance of Escherichia species
with or without Klebsiella species in all patients at pre- and
post-HSCT time points, with the exception of day 217 to
24 pre-HSCT for patient A in whom these fluctuations were
associated with dominance of Clostridia cluster XIVa (Fig
E1, A-C). Increases in membrane transporters over HSCT for
patient A were associated with appearance of Enterococcus
species at day 240 and days 144 to 171 and Clostridia clus-
ter XIVa from day 217 to 24 (Fig E1, D). Association be-
tween fluctuations in functions and specific bacterial taxa
would be expected given that functional data are computation-
ally derived from 16S rRNA bacterial taxa data. Some fluctu-
ations predicted bacterial motility and transport functions were
associated with time between HSCT and neutrophil engraft-
ment for patient B (Fig 2, B; Fig E1, B and E) and develop-
ment of fevers and grade II skin GvHD from day 130 in
patient D (Fig 2, C; Fig E1, C and F). No other clinical corre-
lations were apparent. These patient-specific changes are diffi-
cult to generalize in this pilot study but may represent periods
of dysbyosis, a process implicated in gastrointestinal immune-
mediated pathologies.
AlthoughUPLC-MS/MSmethodologywas optimized to detect
the maximum number of sample metabolites, this study did not
identify specific metabolites. Future work should focus on
identification of specific bacterial metabolites with immunoreg-
ulatory potential. Butyrate, a short-chain fatty acid produced by
colonic bacteria, increases peripheral regulatory T lymphocytes
in vitro and in vivo, through histone deacetylase inhibition
(HDACi7). Vorinostat, another HDACi, gave low rates of
moderate-severe acute GvHD in combination with standard
GvHD prophylaxis in a phase I/II clinical trial.8 Further work is
needed to define the role of butyrate, butyrate-producing bacteria,
and HDACi in HSCT in the SCID population. Genes involved in
flagella assembly were predicted to fluctuate and although testing
this prediction through metagenomic sequencing is outside the
scope of this study, future work is warranted given the suggested
role of flagellin in GvHD prevention in mice.9
HSCT disrupts structure and function of the gut microbiota in
SCID, which is an important consideration when current treat-
ment involves significant use of antibiotics and chemotherapy
with gastrointestinal toxicity.
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http://dx.doi.org/10.1016/j.jaci.2016.02.019IgE antibodies and response to
cow’s milk elimination diet in pedi-
atric eosinophilic esophagitisTo the Editor:
There are 3 lines of evidence supporting cow’s milk as a
relevant problem food for pediatric patients with eosinophilic
esophagitis (EoE). First, studies of the 6-food elimination diet
followed by reintroduction of food groups showed that when
cow’smilk was reintroduced, symptoms or inflammation returned
in up to 74% of patients. Second, it was subsequently reported in a
retrospective analysis that a significant proportion of patients with
EoE (65%) responded to single food elimination of cow’s milk.1
In our own recent prospective study of patients treated with cow’s
milk elimination, we also found that 65% of the patients had less
than 15 eosinophils/hpf after 6 to 8 weeks of treatment.2 Finally, a
striking proportion of pediatric patients with EoE have low levels
of serum IgE antibodies to cow’s milk.3 Our objective for the
current analysis was to evaluate the relationship between specific
METHODS
Patients and samples
Patients and sample acquisition have been previously described.E1 Briefly,
clinical data and longitudinal daily stool samples were collected following
informed parental consent. Stool samples were stored at 2208C to 2808C
before analysis. All 88 samples spanning 1 to 3 months pre- and post-HSCT
for 3 patients with SCID who had 16S rRNA gene sequences were subjected
to PICRUSt (phylogenetic investigation of communities by reconstruction
of unobserved statesE2) computational prediction of microbiota gene
functions. Fifty-four samples spanning 1 to 3 months pre- and post-HSCT
for 3 patients with SCID were selected for metabolomics analysis using
UPLC-MS/MS based on known 16S rRNA gene profiles and occurrence of
clinical events.
Prediction of the bacterial gene functions from 16S
rRNA gene sequences
Eighty-eight sequences from our previous studyE1 were obtained from
MG-RAST (accession numbers 4634227.3-4634323.3) and analyzed using
PICRUSt v1.0E2 to predict the metabolic function of the bacterial community.
Metabolomic profiling using UPLC-MS/MS
Water, methanol, and acetonitrile (ACN)were liquid chromatographymass
spectrometry (LCMS) grade (Sigma-Aldrich, Dorset, United Kingdom).
Metabolites were extracted from 100 mg stool and homogenized in cold
80% methanol by vortexing for 15 minutes at 48C, centrifuged at 10,000g for
10 minutes at 48C, and the supernatant was lyophilized in a freeze dryer before
storage at2808C. Samples were resuspended in 1mL and diluted a further 1:1
in initial start phase buffer (5% ACN).
Stool metabolite profiling was performed using reverse-phase UPLC-MS/
MS. AnAccucore C18 column (2.6mm, 1503 2.1mm)was used at 408Cwith
a 3.0 mL injection and 300 mL/min flow rate throughout. A multistep liquid
chromatography gradient was used with 5% ACN increasing to 95% ACN
over 22 minutes, followed by 8-minute wash and reequilibration. Samples
were run randomly in triplicate. A Q-Exactive (Thermo, Wilmington, Mass)
was used for the MS, performed using heated electrospray ionization (HESI)
with high resolution (70,000) and positive and negative switching. The mass
range was set from 100 to 1000 m/z. SIEVE (Version 2.2) was used to process
the Thermo RAW files using the recommended thresholds. MS1-based
identification of specific metabolites is inaccurate, and significant metabolites
did not correspond to in-house standards. Further identification beyond the
mass and retention time was not attempted.
Statistical analysis
Metabolomic profiles from SIEVE (version 2.2) were analyzed by
multivariate PLS-DA using SIMCA 13.0 (Umetrics, Stockholm, SwedenE3).
To check that data were adhering to multivariate normalities, Hotelling’s T2
tolerance limits were calculated and set at 0.95. Coefficient analysis on the
PLS-DA data was used to identify metabolites significantly associated with
a pre- or post-HSCT metabolite profile at a 95% confidence.
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FIG E1. Level 3 PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved
states) analysis for bacterial cell motility expression (A-C) and membrane transport expression (D-E) for pa-
tients A, B, and D. T (blue)—day of HSCT. N (green)—day of neutrophil engraftment. Conditioning (yellow):
Treo/flu/C1H—treosulfan, fludarabine, Campath. Antibiotics (black): T—teicoplanin; M—meropenem;
S—co-trimoxazole; C—ceftazidime; V—vancomycin; A—amikacin; Aug—co-amoxiclav. Clinically signifi-
cant complications noted (orange).
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TABLE E1. Patient and HSCT details
Patient Diagnosis
Age at
admission (wk)
Age at
HSCT (wk) Conditioning
Donor/
source Nutrition Complications
Baby A X-linked common
gamma chain
34 41 Treosulphan,
fludarabine,
Campath
MUD/cord NG enteral feeds to day 17;
PN day 17 to 145,
NG feeds reintroduced
gradually from day 116
Pneumocystis jiroveci
pneumonia pre-HSCT,
slow neutrophil engraftment,
fungal chest infection
Baby B RAG I <1 6 Treosulphan,
fludarabine,
Campath
MFD/PBSC Breast-fed until day 236
then bottle feeds with
NG top up feed day 15 to
126 and day 145 onward
Disseminated adenovirus,
CVL infection, GvHD
skin grade I
Baby D X-linked common
gamma chain
<1 5 Nil MSD/BMT Breast-fed throughout except for
NG feeds day 139 to 142
GvHD skin grade II,
CMV infection
Reprinted with permission from Lane et al.E1
BMT, Bone marrow transplant; CMV, cytomegalovirus; CVL, central venous line; MFD, matched family donor; MSD, matched sibling donor; MUD, matched unrelated donor;
NG, nasogastric feeds; PBSC, peripheral blood stem cells; PN, parenteral nutrition.
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